The DOI matches its Crossref record; 280 of the 280 references it cites were found in a registry or an index.
Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Open accessAbstract
Apolipoprotein (apo) B, the critical structural protein of the atherogenic lipoproteins, has two major isoforms: apoB48 and apoB100. ApoB48 is found in chylomicrons and chylomicron remnants with one apoB48 molecule per chylomicron particle. Similarly, a single apoB100 molecule is contained per particle of very-low-density lipoprotein (VLDL), intermediate density lipoprotein, LDL and lipoprotein(a). This unique one apoB per particle ratio makes plasma apoB concentration a direct measure of the number of circulating atherogenic lipoproteins. ApoB levels indicate the atherogenic particle concentration independent of the particle cholesterol content, which is variable. While LDL, the major cholesterol-carrying serum lipoprotein, is the primary therapeutic target for management and prevention of atherosclerotic cardiovascular disease, there is strong evidence that apoB is a more accurate indicator of cardiovascular risk than either total cholesterol or LDL cholesterol. This review examines multiple aspects of apoB structure and function, with a focus on the controversy over use of apoB as a therapeutic target in clinical practice. Ongoing coronary artery disease residual risk, despite lipid-lowering treatment, has left patients and clinicians with unsatisfactory options for monitoring cardiovascular health. At the present time, the substitution of apoB for LDL-C in cardiovascular disease prevention guidelines has been deemed unjustified, but discussions continue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–280 of 280
Lipidomics of Bioactive Lipids in Acute Coronary Syndromes
Solati, Z., & Ravandi, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051051 · Cited by 42
Matthan, N. R., Jalbert, S. M., Lamon‐Fava, S., Dolnikowski, G. G., Welty, F. K., Barrett, P. H. R., Schaefer, E. J., & Lichtenstein, A. H. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000172629.12846.b8 · Cited by 41
Hurt‐Camejo, E., & Camejo, G. (2018) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd5030036 · Cited by 41
Pulai, J. I., Neuman, R. J., Groenewegen, A. W., Wu, J., & Schonfeld, G. (1998) · American Journal of Medical Genetics · Cited by 40
Nutritional management of hyperapoB
Lamantia, V., Sniderman, A. D., & Faraj, M. (2016) · Nutrition Research Reviews · doi:10.1017/s0954422416000147 · Cited by 40
Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile
Blauw, L. L., Noordam, R., Soidinsalo, S., Blauw, C. A., Li‐Gao, R., de Mutsert, R., Berbée, J. F. P., Wang, Y., van Heemst, D., Rosendaal, F. R., et al. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-018-0301-5 · Cited by 40
Delatour, V., Clouet-Foraison, N., Gaie-Levrel, F., Marcovina, S. M., Hoofnagle, A. N., Kuklenyik, Z., Caulfield, M. P., Otvos, J. D., Krauss, R. M., Kulkarni, K. R., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.288746 · Cited by 39
Small, dense LDL cholesterol and apolipoprotein B: Relationship with serum lipids and LDL size
Vekić, J., Zeljković, A., Jelić‐Ivanović, Z., Spasojević‐Kalimanovska, V., Bogavac‐Stanojević, N., Memon, L., & Spasić, S. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.06.035 · Cited by 39
Sidney, S., Sorel, M. E., Quesenberry, C. P., Jaffe, M. G., Solomon, M. D., Nguyen‐Huynh, M. N., Go, A. S., & Rana, J. S. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.02.014 · Cited by 39
Mechanistic Insights to Target Atherosclerosis Residual Risk
Alkhalil, M. (2019) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2019.06.004 · Cited by 39
PCSK9 in cholesterol metabolism: from bench to bedside
Reiss, A. B., Shah, N. B., Muhieddine, D., Zhen, J., Yudkevich, J., Kasselman, L. J., & DeLeon, J. R. (2018) · Clinical Science · doi:10.1042/cs20180190 · Cited by 38
Self-citationHepatic Regulation of Apolipoprotein B
Avramoglu, R. K., & Adeli, K. (2004) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/b:remd.0000045100.66675.92 · Cited by 37
Vaccination against atherosclerosis: An overview
Amirfakhryan, H. (2019) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2019.07.003 · Cited by 36
ApoB: The Power of Physiology to Transform the Prevention of Cardiovascular Disease
Sniderman, A. D., Pencina, M. J., & Thanassoulis, G. (2019) · Circulation Research · doi:10.1161/circresaha.119.315019 · Cited by 35
Colhoun, H. M., Leiter, L. A., Müller-Wieland, D., Cariou, B., Ray, K. K., Tinahones, F. J., Domenger, C., Letierce, A., Israel, M., Samuel, R., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0991-1 · Cited by 33
Prevalence of LDL atherogenic phenotype in patients with systemic lupus erythematosus
Olusi, S. O., & George (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s17015 · Cited by 32
Cao, J., Steffen, B. T., Guan, W., Remaley, A. T., McConnell, J. P., Palamalai, V., & Tsai, M. Y. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.12.013 · Cited by 31
Plasma apolipoproteins A-I and B in survivors of myocardial infarction and in a control group
Graziani, M. S., Zanolla, L., Righetti, G., Marchetti, C., Mocarelli, P., & Marcovina, S. M. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.1.134 · Cited by 31
Haynes, R., Valdés‐Márquez, E., Hopewell, J. C., Chen, F., Li, J., Parish, S., Landray, M., Armitage, J., Haynes, R., Valdés‐Márquez, E., et al. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.06.012 · Cited by 31
Hirano, T., Kodera, R., Hirashima, T., Suzuki, N., Aoki, E., Hosoya, M., Oshima, T., Hayashi, T., Koba, S., Ohta, M., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.62789 · Cited by 31
The Pharmacology and Therapeutic Use of Dabigatran Etexilate
Spinler, S. A. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011432169 · Cited by 30
Functions of cholesterol ester transfer protein and relationship to coronary artery disease risk
Tall, A. R. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.08.006 · Cited by 30
Brodsky, J. L. (2004) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2004.01.004 · Cited by 29
Yadav, R., Liu, Y., Kwok, S., Hama, S., France, M. W., Eatough, R., Pemberton, P., Schofield, J. D., Siahmansur, T. J., Malik, R. A., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001508 · Cited by 29
ApoB versus non-HDL-cholesterol: Diagnosis and cardiovascular risk management
de Nijs, T., Sniderman, A. D., & Graaf, J. D. (2013) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2013.847897 · Cited by 29
Apolipoprotein B, the villain in the drama?
Yu, Q., Zhang, Y., & Xu, C. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.08.037 · Cited by 28
BMI modifies the effect of dietary fat on atherogenic lipids: a randomized clinical trial
Sundfør, T. M., Svendsen, M., Heggen, E., Dushanov, S., Klemsdal, T. O., & Tonstad, S. (2019) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqz113 · Cited by 28
Isakadze, N., Mehta, P. K., Law, K. L., Dolan, M., & Lundberg, G. P. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0753-0 · Cited by 27
Kolovou, G. D., Diakoumakou, O., Kolovou, V., Fountas, E., Stratakis, S., Zacharis, E. A., Liberopoulos, E. N., Matsouka, F., Tsoutsinos, A. J., Mastorakou, I., et al. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319870007 · Cited by 27
Varvel, S. A., Dayspring, T. D., Edmonds, Y., Thiselton, D. L., Ghaedi, L., Vörös, S., McConnell, J. P., Sasinowski, M., Dall, T., & Warnick, G. R. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.11.005 · Cited by 26
Apolipoprotein B correlates with intra-plaque necrotic core volume in stable coronary artery disease
Ohwada, T., Sakamoto, T., Kanno, Y., Yokokawa, S., Amami, K., Nakazato, K., Takeishi, Y., & Watanabe, K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212539 · Cited by 26
Endoplasmic reticulum quality control in lipoprotein metabolism
Koerner, C. M., Roberts, B. S., & Neher, S. B. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110547 · Cited by 26
Viktorínová, A., Malickova, D., Sviteková, K., Choudhury, S., & Krizko, M. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108858 · Cited by 26
Herscovitz, H., Derksen, A., Walsh, M. T., McKnight, C. J., Gantz, D., Hadzopoulou‐Cladaras, M., Zannis, V. I., Curry, C., & SMALL, D. M. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32335-x · Cited by 25
LDL-Cholesterin und kardiovaskuläre Ereignisse: je niedriger desto besser?
Weitgasser, R., Ratzinger, M., Hemetsberger, M., & Siostrzonek, P. (2016) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-016-0518-2 · Cited by 25
Aneni, E. C., Osondu, C. U., Cruz, J. D. L., Martin, S. S., Blaha, M. J., Younus, A., Feldman, T., Agatston, A. S., Veledar, E., & Nasir, K. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.40741 · Cited by 25
Enkhmaa, B., Anuurad, E., Zhang, W., & Berglund, L. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.04.035 · Cited by 24
McAlister, F. A., Quan, H., Fong, A., Jin, Y., C̆ujec, B., & Johnson, D. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.089 · Cited by 24
CETP Inhibitors — A New Inning?
Hegele, R. A. (2017) · New England Journal of Medicine · doi:10.1056/nejme1711407 · Cited by 23
Doonan, L. M., Fisher, E. A. A., & Brodsky, J. L. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.03.010 · Cited by 22
Efficacy and Safety of Evinacumab for the Treatment of Hypercholesterolemia: A Meta-Analysis
Jin, M., Meng, F., Yang, W., Liang, L., Wang, H., & Zhenyan, F. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001073 · Cited by 22
Lamantia, V., Bissonnette, S., Wassef, H., Cyr, Y., Baass, A. W., Dufour, R., RABASA-LHORET, R. P. R., & Faraj, M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.09.013 · Cited by 21
Zhao, X., Ma, X.-B., Luo, X., Shi, Z., Deng, Z., Jin, Y., Xiao, Z., Tan, L., Liu, P., Jiang, S., et al. (2020) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-020-00463-w · Cited by 21
Sniderman, A. D. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.8.1310 · Cited by 20
Recent Advances in the Development of Vaccines for Diabetes, Hypertension, and Atherosclerosis
Lu, K., Su, B., & Meng, X. (2018) · Journal of Diabetes Research · doi:10.1155/2018/1638462 · Cited by 20
An Equation to Estimate the Concentration of Serum Apolipoprotein B
Hwang, Y., Ahn, H. Y., Lee, W. J., Park, C., & Park, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051607 · Cited by 19
Hermans, M. P., Ahn, S. A., & Rousseau, M. F. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-56 · Cited by 19
Trompet, S., Packard, C. J., & Jukema, J. W. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000476 · Cited by 19
Dansinger, M. L., Williams, P. T., Superko, H. R., & Schaefer, E. J. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1094-4 · Cited by 17
Cartier, L.-J., St-Cœur, S., Robin, A., Lagacé, M., & Douville, P. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.12.002 · Cited by 17
Pharmacokinetics of current and emerging treatments for hypercholesterolemia
Tomlinson, B., Chan, P., Zhang, Y., Liu, Z., & Lam, C. W. K. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1749261 · Cited by 17
Ying, Q., Chan, D. C., & Watts, G. F. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.603910 · Cited by 17
Should apolipoprotein B replace LDL cholesterol as therapeutic targets are lowered?
Meeusen, J. W., Donato, L. J., & Jaffe, A. S. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000313 · Cited by 16
Rahman, F., Blumenthal, R. S., Jones, S. R., Martin, S. S., Gluckman, T. J., & Whelton, S. P. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0713-2 · Cited by 16
Removal of Chylomicron Remnants from the Bloodstream is Delayed in Aged Subjects
Vinagre, C. G. C., Freitas, F. R., Mesquita, C. H., Vinagre, J. C., Mariani, A. C., Filho, R. K., & Maranhão, R. C. (2018) · Aging and Disease · doi:10.14336/ad.2017.1003 · Cited by 16
In Pursuit of an Atherosclerosis Vaccine: Chasing the Holy Grail
Chyu, K., & Shah, P. K. (2018) · Circulation Research · doi:10.1161/circresaha.118.313842 · Cited by 16
Evinacumab for treatment of familial hypercholesterolemia
Warden, B. A., & Duell, P. B. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1955349 · Cited by 16
Apolipoprotein B measurement: need for standardization
Contois, J. H., & Delatour, V. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.017 · Cited by 15 · cited 1×
“The wide acceptance of LDL-C coupled with the added expense and complication of measuring apoB has thus far prevented a major shift toward clinical application of plasma apoB at the point-of-care [275,276].”
BackgroundBays, H. E., Shah, A. K., Lin, J., Sisk, C. M., Dong, Q., & Maccubbin, D. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11631530-000000000-00000 · Cited by 15
Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans
Adiels, M., Mardinoğlu, A., Taskinen, M., & Borén, J. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00342 · Cited by 15
Control del perfil lipídico global
Blasco, M., & Ascaso, J. F. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.10.002 · Cited by 15
Dabigatran etexilate and reduction in serum apolipoprotein B
Joseph, P. G., Paré, G., Wallentin, L. C., Connolly, S. J., Yusuf, S., Wang, J., Ezekowitz, M. D., Eikelboom, J. W., Siegbahn, A. G., Reilly, P. A., et al. (2015) · Heart · doi:10.1136/heartjnl-2015-307586 · Cited by 14
Rizvi, A. A., Cuadra, S., Nikolić, D., et al. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140330193653 · Cited by 14
Ivert, T., Malmström, H., Hammar, N., Carlsson, A. C., Wändell, P. E., Holzmann, M. J., Jungner, I., Ärnlöv, J., & Walldius, G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201972 · Cited by 14
Ballantyne, C. M., Gleim, G. W., Liu, N., Sisk, C. M., Johnson‐Levonas, A. O., & Mitchel, Y. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.11.004 · Cited by 13
Brunelli, R., Greco, G., Barteri, M., Krasnowska, E. K., Mei, G., Natella, F., Pala, A., Rotella, S., Ursini, F., Zichella, L., et al. (2003) · The FASEB Journal · doi:10.1096/fj.02-1181fje · Cited by 12
Elevated apolipoprotein B as a risk-enhancing factor in 2018 cholesterol guidelines
Grundy, S. M., & Stone, N. J. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.009 · Cited by 12
Soran, H., Ho, J. H., Adam, S., & Durrington, P. N. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000614 · Cited by 11
Dietary strategies for cardiovascular health
Dieter, B. P., & Tuttle, K. R. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.12.007 · Cited by 10
Pu, X., Sale, M. E., Yang, F., Zhang, Y., Davis, J. D., & Al-Huniti, N. H. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12711 · Cited by 10
Chang, T.-Y., & Chen, J. (2020) · Coronary Artery Disease · doi:10.1097/mca.0000000000001004 · Cited by 9
Nghiem, N., Knight, J., Mizdrak, A., Blakely, T. A., & Wilson, N. (2019) · Scientific Reports · doi:10.1038/s41598-019-55372-8 · Cited by 7
Erythrocyte‐bound apolipoprotein B in atherosclerosis and mortality
de Vries, M. A., van Santen, S., Klop, B., van der Meulen, N., van Vliet, M., van de Geijn, G. M., van Beek, E. M., Birnie, E., Liem, A. H., de Herder, W. W., et al. (2017) · European Journal of Clinical Investigation · doi:10.1111/eci.12728 · Cited by 6
Karásek, D., Vaverková, H., Cibičková, Ľ., Gajdová, J., & Kučerová, V. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.01.020 · Cited by 6
Hwang, Y., Ahn, H. Y., Han, K. H., Park, H., & Park, C. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0549-8 · Cited by 6
Is Anacetrapib Better Than Its CETP Inhibitor Counterparts?
Grabie, M., Tai, C.-H., & Frishman, W. H. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000245 · Cited by 6
Chen, Y., Shang, D., Shao, J., Dai, S., Ge, X., Hao, C., & Zhu, T. (2020) · Nephrology · doi:10.1111/nep.13759 · Cited by 4
Feng, X., Berklein, F. C., Rane, P., et al. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07028-3 · Cited by 3
Small Dense LDL Tied to Diabetic Retinopathy-Similarity to Atherosclerosis
Hirano, T. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed174 · Cited by 3
Some causes of poor adherence to long-term statin therapy and their solution
Soška, V., & Kyselák, O. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.128 · Cited by 2
Cited by
Peña-Jorquera, H., Cid-Jofré, V., Landaeta-Díaz, L., Petermann-Rocha, F., Martorell, M., Zbinden-Foncea, H., Ferrari, G., Jorquera-Aguilera, C., & Cristi-Montero, C. (2023) · Nutrients · doi:10.3390/nu15143244 · Cited by 103
RNA-binding proteins in vascular inflammation and atherosclerosis
Sachse, M., Tual-Chalot, S., Ciliberti, G., Amponsah-Offeh, M., Stamatelopoulos, K., Gatsiou, A., & Stellos, K. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.008 · Cited by 29
Metadata
- Authors
- Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., De Leon, J., Glass, A. D., & Reiss, A. B.
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2021-10-08
- Volume
- 11
- Issue
- 10
- Pages
- 690
- ISSN
- 2218-1989 (ISSN-L)
- OpenAlex
- W3207756665
- Cited by
- 270
- References
- 280
- FWCI
- 35.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.